作者: Fabrizio Fabrizi , Paul Martin , Vivek Dixit , Maria Brezina , James Russell
DOI: 10.1159/000013482
关键词:
摘要: Patients on chronic hemodialysis (HD) treatment have been identified by serological testing, including second- and third-generation enzyme-linked immunosorbent assay (ELISA), as a high-risk group for